MIGREN RIVOJLANISHIDA GOMOTSISTEIN GENETIK PREDIKTORLARINING LABORATOR DIAGNOSTIKASI
Abstrakt
Maqolada migren patogenezi rivojlanishining turli variantlari o‘rganildi. Yuqorida tilga olingan patogenezga qo‘shimcha tarzda migrenning boshqa gipotezi kelib chiqdi, u gomotsistein bilan bog‘liq, ya’ni gomotsisteinning oshgan konsentratsiyasi keyinchalik gomotsistein va stressning oksidlanishi bilan glutation ishlab chiqishni pasaytiradi.
Nashr sanasi
Mualliflar haqida
Adabiyotlar ro'yxati
Tommaso MD, Losito L, Livrea P. The role of homocysteine in the pathogenesis and development of migraine. Cephalalgia 2005; 25: 823– 1020.
Lea A, Menon S, Colson NJ et al. Analysis of the MTHFR C677T variant with migraine phenotypes. BMC Res. Notes 2010; 3: 213. DOI: https://doi.org/10.1186/1756-0500-3-213
Gavgani SC, Hoseinian MM. Comparative study on homocysteine levels in migraine patients and normal peoples. Ann. Biol. Res. 2012; 3(4): 1804– 7.
Hosseini M, Houshmad M, Ebraini A. MTHFR polymorphism and breast cancer risk. Arch. Med. Sci. 2011; 7: 134– 7. DOI: https://doi.org/10.5114/aoms.2011.20618
Antoniades C, Shirodaria C, Leeson P et al. MTHFR 677 C>T polymorphism reveals functional importance for 5-methyltetrahydrofolate, no homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation 2009; 119: 2507– 15. DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.808675
Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The homozygous C677T mutation in the methylenetatrahydrofolate reductase gene is generic risk factor for migraine. Am. J. Med. Genet. 2000; 96: 762– 4. DOI: https://doi.org/10.1002/1096-8628(20001204)96:6<762::AID-AJMG12>3.0.CO;2-X
Lorenz AL, Kahre T, Mihailov E et al. Are methylenetetrahydrofolate reductase (MTHFR) gene polymorphism C677T and A1298 C associated with higher risk of pediatric migraine in boys and girls? J. Biom. Sci. Eng. 2014; 7: 464– 72. DOI: https://doi.org/10.4236/jbise.2014.78049
Liu R, Geng P, Ma M et al. MTHFR C677T ploymorfism and migraine risk: a meta-analysis. J. Neurol. Sci. 2014; 336: 68– 73. DOI: https://doi.org/10.1016/j.jns.2013.10.008
Moskowitz MA. The neurobiology of vascular head pain. Ann. Neurol. 1984; 16: 157– 68. DOI: https://doi.org/10.1002/ana.410160202
Lea R, Colson N, Quinlan S, McMillan J, Griffiths L. The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet. Genomics 2009; 19: 422– 8. DOI: https://doi.org/10.1097/FPC.0b013e32832af5a3
Shaik MM, Gan SH. Vitamin supplementation as possible prophylactic treatment against migraine with aura and menstrual migraine. BioMed. Res. Intern. 2015. https://doi.org/10.1155/2015/469529 DOI: https://doi.org/10.1155/2015/469529
Tchantchou F, Graves M, Falcone D, Shea TB. S-adenosyl-methionine mediates glutathione efficacy by increasing glutathione-S-transferase activity: implications for the S-adenosylmethionine as a protective dietary activity supplement. J. Alzheimer Dis. 2008; 14: 323– 8. DOI: https://doi.org/10.3233/JAD-2008-14306
Boldyrev AA. Molecular mechanisms of homocysteine toxicity. Biochem. (Moscow) 2009; 74: 589– 98. DOI: https://doi.org/10.1134/S0006297909060017
Cararo JH, Streck EL, Schuck PF, Ferreira C. Carnosine and related peptides: potential in age-related disorders. Aging. Dis. 2015; 5: 369– 79. DOI: https://doi.org/10.14336/AD.2015.0616